选择性5-羟色胺再摄取抑制剂与白内障风险:病例对照分析
基于英国临床实践研究数据链(CPRD)的病例对照研究纳入206931例首次白内障患者及等量匹配对照,评估SSRI及其他抗抑郁药暴露与白内障风险的关联。长期使用SSRI(≥20次处方)整体未与白内障风险升高相关(调整OR 0.99;95%CI 0.94-1.03),但40-64岁亚组长期使用者风险轻度升高(调整OR 1.24;95%CI 1.15-1.34)。作者结论认为SSRI使用未与白内障风险升高相关,但年轻人群中的轻度升高需进一步研究。
要点
- 长期使用SSRI(≥20次处方)整体未与白内障风险升高相关(调整OR 0.99;95%CI 0.94-1.03)。
- 40-64岁亚组中,长期SSRI使用者较非使用者白内障风险轻度升高(调整OR 1.24;95%CI 1.15-1.34)。
- 作者结论认为SSRI使用未与白内障风险升高相关,但65岁以下人群长期使用的轻度OR升高需进一步研究。
核心结论
- 在这组数据中,SSRI使用未与白内障风险升高相关。
- 65岁以下个体长期使用SSRI相关的轻度OR升高需在进一步研究中探究。
研究设计与样本
- 病例对照研究,研究人群源自英国临床实践研究数据链(CPRD)。
- 纳入1995年至2015年间年龄≥40岁的首次白内障患者,并按年龄、性别、全科诊所、白内障记录日期(即索引日期)及索引日期前CPRD病史年数匹配等量无白内障对照。
- 采用条件logistic回归分析,调整体质指数、吸烟、高血压、糖尿病和全身性类固醇使用。
- 暴露指标为SSRI处方数和其他抗抑郁药处方数,并进一步探索单一SSRI药物的互斥使用。
- 敏感性分析中将索引日期前移2年,并限制分析于无既往青光眼诊断的病例和对照。
主要发现
- 共识别206931例白内障病例及等量匹配对照。
- 当前长期使用SSRI(≥20次处方)未与白内障风险升高相关(调整OR 0.99;95%CI 0.94-1.03)。
- 在40至64岁患者亚组中,长期SSRI使用者较非使用者白内障风险轻度升高(调整OR 1.24;95%CI 1.15-1.34)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 65岁以下个体长期使用SSRI相关的轻度OR升高需在进一步研究中探究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Use of selective serotonin reuptake inhibitors (SSRIs) has been associated with an increased cataract risk. We aimed to assess cataract risk after exposure to SSRI or to other antidepressant drugs in a large electronic primary care database. DESIGN: Case-control study. PARTICIPANTS: The study population was derived from the UK-based Clinical Practice Research Datalink (CPRD). We included patients with first-time cataract aged ≥40 years between 1995 and 2015 and an equal number of cataract-free controls matched on age, sex, general practice, date of cataract recording (i.e., index date), and years of history in the CPRD before the index date. METHODS: We conducted conditional logistic regression analyses adjusted for body mass index, smoking, hypertension, diabetes, and systemic steroid use. Exposure of interest was the number of SSRI prescriptions and prescriptions for other antidepressant drugs. We further explored mutually exclusive use of single SSRI substances. In sensitivity analyses, we shifted the index date backwards by 2 years, and we restricted our analyses to cases and controls without a prior glaucoma diagnosis. MAIN OUTCOME MEASURES: Relative risk estimates as odds ratios (ORs) with 95% confidence intervals (CIs). RESULTS: We identified 206 931 cataract cases and the same number of matched controls. Current long-term use of SSRI (≥20 prescriptions) was not associated with an increased cataract risk (adjusted OR, 0.99; 95% CI, 0.94-1.03). However, in a subset of patients aged 40 to 64 years, we found a slightly increased risk of cataract for long-term SSRI users (adjusted OR, 1.24; 95% CI, 1.15-1.34) compared with nonusers. CONCLUSIONS: In these data, use of SSRI was not associated with an increased risk of cataract. The slightly increased OR for individuals younger than 65 years of age in association with long-term SSRI use needs to be investigated in further studies.
引用
- Becker C, Jick SS, Meier CR, et al. Selective Serotonin Reuptake Inhibitors and Cataract Risk: A Case-Control Analysis. Ophthalmology. 2017. PMID: 28571893. doi:10.1016/j.ophtha.2017.05.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。